(Q36764031)

16 August 2017

1 reference

title

Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes (English)

1 reference

16 August 2017

1 reference

Carolyn F Deacon

1

0 references

language of work or name

English

0 references

publication date

1 April 2007

1 reference

Expert Opinion on Investigational Drugs

16 August 2017

published in

1 reference

16 August 2017

volume

16

1 reference

16 August 2017

issue

4

1 reference

16 August 2017

page(s)

533-545

1 reference

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.533

Beta- and alpha-cell dysfunction in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.533

Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.533

Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.533

Long-term efficacy of sulfonylureas: a United Kingdom Prospective Diabetes Study perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.533

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.533

On the physiology of GIP and GLP-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.533

Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.533

Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.533

Therapeutic strategies based on glucagon-like peptide 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.533

Management of Type 2 diabetes: the role of incretin mimetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.533

Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.533

(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.533

1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.533

Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.533

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.533

Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.533

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.533

Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.533

Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.533

Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.533

Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.533

DPP-4 inhibitors and their potential role in the management of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.533

Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.533

Inhibitors of dipeptidyl peptidase IV--recent advances and structural views

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.533

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.533

Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.533

Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.533

Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.533

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.533

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.533

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.533

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.533

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.533

Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.533

Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.533

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.533

Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.533

Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.533

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.533

Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.533

10.1517/13543784.16.4.533

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference